Apotex recalls allergy nasal spray due to glass particles

Apotex yesterday issued a voluntary recall of one lot of fluticasone propionate allergy nasal spray devices, noting that they may contain small glass particles. The company first discovered the issue thanks to a customer complaint. The glass particles could block the device’s actuator, according to Apotex, and impact the pump’s functionality. Get the full story at our sister site, Drug Delivery Business News. The post Apotex recalls allergy nasal spray due to glass particles appeared first on MassDevice.
Source: Mass Device - Category: Medical Devices Authors: Tags: Drug-Device Combinations Food & Drug Administration (FDA) Pharmaceuticals Recalls Regulatory/Compliance Respiratory apotex Source Type: news

Related Links:

ConclusionAllergy skin tests are reliable and justified for diagnosing allergies in cases of persistent or recurrent oral diseases. This is the only way to confirm allergies and is the basis for consequent allergen avoidance for the benefit of the patient.
Source: Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology - Category: ENT & OMF Source Type: research
NIH oversight panel no longer plans to review all applications for gene therapy experiments
Source: The Doctors Lounge - Psychiatry - Category: Psychiatry Tags: Cardiology, Dermatology, Endocrinology, Family Medicine, Geriatrics, Gastroenterology, Gynecology, Infections, AIDS, Internal Medicine, Allergy, Nephrology, Neurology, Oncology, Ophthalmology, Orthopedics, ENT, Pathology, Pediatrics, Pharmacy, Psychiatry, Source Type: news
CONCLUSION: It is concluded that nutraceuticals possess enormous health benefits and their interventions can be highly beneficial in the prevention/reduction of CVDs and related disorders such as atherosclerosis, hypertension, heart attack and stroke. The findings of this review provide an update on the emerging uses of nutraceuticals, functional foods, and herbal remedies in humans. Nevertheless, large-scale randomized, placebo-controlled, double-blind clinical trials are needed to confirm the health benefit claims about nutraceuticals and herbal products to establish their long-term safety and to resolve the controversy ...
Source: Recent Patents on Inflammation and Allergy Drug Discovery - Category: Allergy & Immunology Tags: Recent Pat Inflamm Allergy Drug Discov Source Type: research
Worsening seen for sleep duration, quality of sleep, and daytime sleepiness
Source: The Doctors Lounge - Psychiatry - Category: Psychiatry Tags: Cardiology, Dermatology, Endocrinology, Family Medicine, Geriatrics, Gastroenterology, Gynecology, Infections, AIDS, Internal Medicine, Allergy, Critical Care, Emergency Medicine, Nephrology, Neurology, Oncology, Ophthalmology, Orthopedics, ENT, Pathology Source Type: news
Condition:   Allergic Rhinitis Intervention:   Other: e-BOOK Sponsor:   Assistance Publique Hopitaux De Marseille Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   HIV Infections Interventions:   Drug: Standard of Care (SOC) Oral ART;   Drug: Oral RPV;   Drug: Oral CAB;   Drug: RPV-LA Loading Dose;   Drug: CAB-LA Loading Dose;   Drug: RPV-LA Maintenance Dose;   Drug: CAB-LA Maintenance Dose Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
  NBCNews: The generic of the lifesaving allergy medication will offer a cheaper alternative to the Mylan’s EpiPen, which has come under fire for massive price hikes. Bystander Epinephrine in Community Anaphylaxis Critical Updates in Assessment &Management of Anaphylaxis Treat Anaphylactic Incidents Before it’s Too Late  
Source: JEMS Patient Care - Category: Emergency Medicine Authors: Tags: News News Videos Patient Care Source Type: news
The Food and Drug Administration Thursday approved a new generic version of the  EpiPen, a move that could drive down the price and increase the availability of the emergency allergy medication auto-injector. The generic version will be made by Teva Pharmaceuticals USA (NYSE:TEVA) in 0.3 mg and 0.15 mg strengths, the New York Times reported.  EpiPen manufacturer Mylan has c ome under intense criticism for raising the price of the medication, which is used by people with severe allergies to prevent…
Source: bizjournals.com Health Care News Headlines - Category: Health Management Authors: Source Type: news
Years after seeking federal approval, Israeli drugmaker gets nod to sell version of life-saving allergy treatment
Source: Health News: CBSNews.com - Category: Consumer Health News Source Type: news
The Food and Drug Administration Thursday approved a new generic version of the  EpiPen, a move that could drive down the price and increase the availability of the emergency allergy medication auto-injector. The generic version will be made by Teva Pharmaceuticals USA (NYSE:TEVA) in 0.3 mg and 0.15 mg strengths, the New York Times reported.  EpiPen manufacturer Mylan has c ome under intense criticism for raising the price of the medication, which is used by people with severe allergies to prevent…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news
More News: Allergy | Allergy & Immunology | Flonase | Flovent | Respiratory Medicine